BIIB vs ZBH · P/E 21, rev $9.89B vs P/E 23, rev $8.23B
Biogen Inc (BIIB) versus Zimmer Biomet Holdings Inc (ZBH) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported ZBH revenue for 2025-12-31 was $8.23B. Net income was $705.1M. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
Not investment advice. Open the BIIB and ZBH stock pages for the full models.
Not investment advice.